Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type 2 Diabetes, Vascular Calcification,...
Phase Not Applicable
Enrollment 1400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Coronary artery calcification (CAC) is a common complication of type 2 diabetes mellitus(T2DM), which can significantly increase all-cause mortality and the incidence of serious cardiovascular events, and increase the burden of the national economy. The epidemiological characteristics and the clinical progress of CAC are still not clear. Moreover, the pathogenesis of CAC has not yet been fully elucidated, and lack of specific diagnostic indicators. Arterial calcification is an active, reversible, and multifactorial biological process like bone formation. It is generally believed that early detection of calcification lesions and active targeted treatment may be the key to prevention and treatment of vascular calcification. In addition, statins are commonly used in patients with dyslipidemia and can stabilize CAC plaque. However, the timing, dosage and effect of statins are controversial. Moreover, our previous study found that the expression of miR-32 is significantly elevated in patients with CAC, and can promoting vascular calcification. Herein, this study is to conduct a prospective cohort study on T2DM patients with CAC in Hunan province through a multidisciplinary and multi-center cooperation model, the main research objectives include the following three parts: ① To identify the prevalence, incidence, and characteristics of CAC in T2DM patients in Hunan province, and to build a risk assessment model. ② To observe the effects of statins on the occurrence and development of CAC in patients with T2DM, and to provide clinical data for the improvement of medication guidelines; ③To observe the dynamic changes of serum miR-32 in the progression of CAC in patients with T2DM, and to explore its possibility as a serological diagnosis or prognostic bio-maker of CAC. The completion of this research project is expected to bring a new breakthrough in the field of early diagnosis, prognosis evaluation, and intervention treatment of patients with T2DM combined with CAC, and provide an important reference for the formulation of cardiovascular disease prevention and control strategy.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • The prevalence and incidence rate of CAC in T2DM (Anticipate completed in December 2026)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2021-06-01
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of South China
Principal Investigators:
  • Liu Jianghua, PhD (STUDY_CHAIR) - The First Affiliated Hospital of University of South China
Contact Information
Study Contact:
Liu Jianghua, PhD
(+86)13407340909
jianghua990@126.com
Fu Chenxiao, PhD
(+86)13469116604
nhfyllwyh@163.com
Liu Jianghua, PhD
The First Affiliated Hospital of University of South China
Interventions
N/A
Study Locations (1 sites)
The First Affiliated Hospital of University of South China, Hengyang, China
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old * Type 2 diabetes is diagnosed according to WHO diagnostic criteria * Low dose prospectively triggered sequential dual-source CT coronary angiography can be performed at baseline investigation * Those subjects are able to understand the purpose and procedure of this study and sign the informed consent voluntarily Exclusion Criteria: * Those have received coronary artery stenting or coronary artery bypass grafting * Those with severe lung (respiratory failure), liver (ALT or AST 3 times normal value or bilirubin increase), renal dysfunction\[GFR \< 45ml/(min.1.73m2) or dialysis patients * Malignant tumor * Mental illness or mental retardation * Pregnant or lactating women or those with fertility planning * Concomitant diseases (hyperparathyroidism, sarcoidosis, amyloidosis) affecting calcium balance and soft tissue calcification * Contraindications of contrast agents * Based on the judgment of the researcher, the compliance is poor and the study could not be completed according to the requirements
Conditions Liver Cancer, Lung Cancer, Breast Cancer...
Phase PHASE1
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. The safety, tolerance, and preliminary clinical efficacy of the TILs will be evaluated.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 — TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.

Primary Outcomes

  • Safety of TILs/CAR-TILs treatment in advanced solid cancers (up to 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2021-01-01
Completion: 2035-01-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Collaborators: Guangdong Zhaotai InVivo Biomedicine Co. Ltd.
Principal Investigators:
  • Zhenfeng Zhang, MD, PhD (PRINCIPAL_INVESTIGATOR) - Second Affiliated Hospital of Guangzhou Medical University
Contact Information
Study Contact:
Zhenfeng Zhang, MD, PhD
+862039195966
zhangzhf@gzhmu.edu.cn
Bingjia He, MD
+862039195965
464677938@qq.com
Zhenfeng Zhang, MD, PhD
+862039195966
zhangzhf@gzhmu.edu.cn
Second Affiliated Hospital of Guangzhou Medical University
Interventions
  • Biological: TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 — TILs and CAR-TILs injection: 1-10×10e7/kg cells for each treatment; 3 or more cycles.
Study Locations (1 sites)
Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260 China
Eligibility Criteria
Inclusion Criteria: 1. Patients with advanced cancers that failed to current available therapies; 2. Life expectancy \>12 weeks; 3. Adequate heart, lung, liver, kidney functions; 4. Available for tumor biopsy or cancerous effusions; 5. Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent. Exclusion Criteria: 1. Had accepted gene therapy before; 2. Severe virus infection such as HBV, HCV, HIV, et al; Known HIV positivity; 3. Active infectious disease related to bacteria, virus, fungi, et al; 4. Other severe diseases that the investigators consider not appropriate; 5. Pregnant or lactating women; 6. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day); 7. Other conditions that the investigators consider not appropriate.
Conditions Ductal Carcinoma in Situ, Extensive Dise...
Phase PHASE2
Enrollment 262
Locations 8 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Ductal carcinoma in situ (DCIS) accounts for approximately 20% of newly diagnosed breast cancer cases. Of these women, 20% require radical management in the form of mastectomy because of the extent of the lesions, which most often manifest as diffuse microcalcifications. This mutilating surgical management contrasts with the excellent prognosis of this pathology and considerably alters the quality of life of patients. Neoadjuvant hormone therapy has shown its efficacy in hormone-dependent infiltrating ductal carcinomas and offers the possibility of conservative surgery after hormone therapy. Adjuvant hormone therapy with Tamoxifen or anti-aromatase drugs has shown its efficacy in the prevention of homo or contralateral recurrence. The HORNEO 01 trial fits perfectly in the current context of surgical de-escalation of ductal carcinomas in situ. The objective of the study is to evaluate the impact of neoadjuvant hormone therapy on the surgical management of extensive DCIS.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tamoxifen 20 mg — Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
  • Drug: Anastrozole 1Mg Tab — Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.

Primary Outcomes

  • Efficacy of neoadjuvant hormonotherapy (6 months of hormonotherapy)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2021-02-03
Completion: 2033-08-01
Eligibility
Age: 40 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 262 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Cancerologie de l'Ouest
Principal Investigators:
  • Victoire BRILLAUD-MEFLAH, MD (PRINCIPAL_INVESTIGATOR) - Institut de Cancérologie de l'Ouest
Contact Information
Study Contact:
Victoire BRILLAUD-MEFLAH, MD
0240679818
Victoire.brillaud-meflah@ico.unicancer.fr
Emilie DEBEAUPUIS
0240679844
emilie.debeaupuis@ico.unicancer.fr
Augustin P REYNARD, MD
augustin.reynard@ico.unicancer.fr
ICO - Site Paul Papin
Interventions
  • Drug: Tamoxifen 20 mg — Tamoxifen will be initiated in non menopausal patients orally for 6 months in a neoadjuvant situation.
  • Drug: Anastrozole 1Mg Tab — Anastrozole will be initiated in menopausal patients orally for 6 months in a neoadjuvant situation.
Study Locations (8 sites)
ICO - Site Paul Papin, Angers, 49055 France
Institut Bergonie, Bordeaux, 33076 France
Institut de cancérologie de Montpellier, Montpellier, 34298 France
Centre Antoine Lacassagne, Nice, 06189 France
Institut Curie - Site de Paris, Paris, 75005 France
Hopital Saint Joseph, Paris, 75014 France
Institut de Cancérologie de l'Ouest, Saint-Herblain, 44805 France
IUCT-O, Toulouse, 31059 France
Eligibility Criteria
Inclusion Criteria: 1. Patient ≥ 40 years old 2. Histological diagnosis of ductal carcinoma in situ without infiltrating contingent 3. Clinical T0N0 4. Estrogen receptor positive (OR+) regardless of progesterone receptor (PR) status 5. Indication for mastectomy 6. DCIS visible on MRI performed with clip sequence 7. Effective contraceptive method for women of childbearing age who are sexually active and who have reported sexual activity. 8. Informing the patient and obtaining free, informed and written consent signed by the patient and the investigator. 9. Affiliated patient or beneficiary of the social security system. Exclusion Criteria: 1. Invasive breast carcinoma 2. Lobular carcinoma in situ 3. pN+ patient 4. Indication for conservative surgery 5. Contraindications to anastrozole or tamoxifen 6. Concomitant treatments that may interact and reduce the efficacy of tamoxifen by interaction with cytochrome CYP2D6. 7. Histologically proven multifocal lesion 8. Contraindication to breast MRI (pace maker, heart valve, metallic implant, neuronal or peripheral stimulator, severe claustrophobia, ...) 9. History of homolateral breast cancer 10. Ongoing contralateral breast cancer 11. Known mutation BRCA1 BRCA2 12. Other cancer in progress at inclusion 13. Pregnant woman, or breastfeeding, 14. Persons deprived of liberty or under guardianship or trusteeship, 15. Impossibility to undergo the medical follow-up of the trial for geographical, social, psychic or psychiatric reasons.
Conditions Decompensated Liver Cirrhosis
Phase Not Applicable
Enrollment 250
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a single center patient registry of patients receiving a transjugular intrahepatic portosystemic shunt (TIPS) at Hannover Medical School. By collecting and analyzing clinical data as well as blood samples, the overall aim is to optimize TIPS therapy (e.g. specify selection criteria).

Design

Study type: Observational Observational model: Cohort Time perspective: Cross Sectional

Interventions / Regimen

  • Procedure: TIPS insertion — Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.

Primary Outcomes

  • Mortality (1 year)
  • Occurrence of (Minimal) Hepatic Encephalopathy (1 year)
  • Change in Nutritional Status (1 year)
  • Change in Quality of Life (1 year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-08-29
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 250 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hannover Medical School
Principal Investigators:
  • Benjamin Maasoumy, PD (PRINCIPAL_INVESTIGATOR) - Hannover Medical School
Contact Information
Study Contact:
Benjamin Maasoumy, PD
+49 511 532-6529
Maasoumy.Benjamin@mha-hannover.de
Benjamin Maasoumy, PD
+49 511 532-6529
Maasoumy.Benjamin@mh-hannover.de
Hannover Medical School
Benjamin Maasoumy, PD
Hannover Medical School
Interventions
  • Procedure: TIPS insertion — Patients are included in the registry if they receive a transjugular intrahepatic portosystemic shunt at Hannover Medical School and provide written informed consent.
Study Locations (1 sites)
Hannover Medical School, Hanover, Lower Saxony 30625 Germany
Eligibility Criteria
Inclusion Criteria: * Liver cirrhosis * Indication for TIPS insertion * Treatment at the Department of Gastroenterology, Hepatology and Endocrinology of Hannover Medical School * Informed consent Exclusion Criteria: * Pregnancy or Lactation * Age \<18 years * Lack of Informed consent * Symptomatic anemia with Hb \<7g/dl
Conditions Advanced Solid Tumors
Phase PHASE1
Enrollment 98
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A Phase I Study of Dose Escalation and Dose Expansion To Evaluate the Safety、Tolerability、Pharmacokinetics and Preliminary Efficacy of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumor.

Design

Study type: Interventional Phases: Phase1 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Paclitaxel Micelles for Injection — Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
  • Drug: Paclitaxel injection — Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.

Primary Outcomes

  • Safety and tolerability of Paclitaxel Micelles for Injection in dose ascending and dose extension as measured by assessment of maximum tolerated dose (MTD) and dose limiting toxicity (DLT). (2 years)
  • The recommended dose for the phase II study (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2021-03-04
Completion: 2026-06-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 98 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: First Affiliated Hospital of Zhejiang University
Collaborators: Hangzhou Dihua Biotechnology Co., LTD.
Principal Investigators:
  • jian liu, master (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital,ZheJiang Univercity
  • xiaochen zhang, docter (PRINCIPAL_INVESTIGATOR) - The First Affiliated Hospital,ZheJiang Univercity
Contact Information
Study Contact:
jian liu, master
+86-13958054006
lindaliu87@zju.edu.com
xiaochen zhang, docter
+86-13957169922
zhangxiaochen74@163.com
Jian Liu, Master
13958054006
lindaliu87@zju.edu.com
The First Affiliated Hospital,ZheJiang Univercity
Interventions
  • Drug: Paclitaxel Micelles for Injection — Paclitaxel Micelles for Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
  • Drug: Paclitaxel injection — Paclitaxel Injection was intravenously administrated for three hours, three weeks constituted one course of treatment.
Study Locations (1 sites)
The First Affiliated Hospital,ZheJiang Univercity, Hanzhou, Zhejiang 310000 China
Eligibility Criteria
Inclusion Criteria: * Participants are required to meet all the criteria below in order to be included in the trial: 1. Confirmed diagnosis of advanced solid tumors by histological or cytological examination, participants have no effective standard anticancer therapy available or is failed to standard anticancer therapy. 2. Male or female patient, aged 18 \~ 70 years. 3. Life expectancy ≥ 3 months. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. 5. Participants with at least 1 measurable tumor lesion and/or assessable non-measurable lesion based on RECIST 1.1. 6. No radiotherapy, chemotherapy, immunotherapy or other anti-tumor therapy (such as experimental drugs, biological agents, Chinese herbal medicine, etc.), surgical treatment (except diagnostic biopsy), or complete recovery from previous surgery within 4 weeks prior to enrollment, and no surgical operation was planned during the study period. 7. No severe hematopoietic abnormalities(no blood transfusion, no blood products, no granulocyte colony-stimulating factor, platelet stimulating factor, or other hematopoietic growth factors were corrected within 14 days prior to the screening phase laboratory examination):Hb≥90g/L , ANC≥1.5×109/L , PLT≥100×109/L. 8. No serious organic disease of heart, liver or kidney:LVEF≥50% ; ALT(Alanine aminotransferase) or AST(Aspartate transaminase)≤2.5×upper limit of normal(ULN)(for patients with hepatic metastases, ALT or AST≤5 × ULN); TBIL(Total bilirubin)≤1.5×ULN; creatinine≤1.5×ULN and CL≥ 60 mL/min\[The calculation formula was as follows: CCR (140- age)× body weight (kg) /0.818× SCR (μmol/L), and female was calculated as ×0.85\]. 9. The coagulation function is normal:PT、APTT and INR≤1.5×ULN。 10. Participants (including partners) who are willing to follow reliable contraceptive measures during the study and until 3 months after the last dosing(such as intrauterine devices \[IUDs\], birth control pills or condoms).Women of child-bearing age must be negative for serum HCG within 14 days prior to study enrolment and must be non-lactating。 11. Participants with voluntarily signature Informed Consent Form (ICF) before the test, and have a full understanding of the test content, process and possible adverse reactions. 12. Participants with good compliance, were available for follow-up, and volunteered to comply with study regulations. Exclusion Criteria: * Eligible participants must not meet any of the following exclusion criteria: 1. Patients with the toxicity of previous antitumor therapy did not return to grade 1 or below (CTCAE 5.0 grade \>1, excluding toxicity such as alopecia and other toxicity judged by investigators to be of no safety risk). 2. Patients with (including suspected) an allergic history to Paclitaxel, or any of its components, or allergic constitution (excluding mild asymptomatic seasonal allergy). 3. Patients with bleeding tendency or who are receiving thrombolytic or anticoagulant therapy. 4. Patients who had been treated with paclitaxel and were determined by the researchers to be resistant. 5. Patients with active central nervous system metastases,But patients with BMs who have received prior treatment and the metastases were stable can participate in the study. 6. Patients with cerebrovascular accident or transient ischemic attack in the previous 6 months were screened. 7. People with active infection and need anti-infection or antiviral treatment. 8. Patients have suffered from other malignant cancers within 5 years (except for cured basal cell carcinoma and cervical carcinoma in situ). 9. Concomitant diseases, as determined by the investigator, that seriously endangers the safety of subjects or affects their completion of the test(such as gastrointestinal bleeding, intestinal obstruction, intestinal paralysis, interstitial pneumonia, pulmonary fibrosis, etc). 10. Patients with a clear history of neurological or psychiatric disorders (including epilepsy and dementia). 11. Patients who have used any drugs that is CYP2C8 and/or CYP3A4 inducer or inhibitor Within 30 days before use of the test drug(including ketoconazole and other imidazole antifungal agents, verapamil, diazepam, quinidine, cyclosporine, teniposide, etoposide, vincrine, testosterone, 17-α diethylstilbestrol, retinoic acid, quercetin, etc). 12. Patients who received blood transfusion and transfusion of blood products, such as albumin, within 2 weeks prior to trial. 13. Patients with peripheral neuropathy above grade II. 14. Patients with history of myocardial infarction(within 6 months prior to enrollment) ,severe or unstable angina, coronary or peripheral artery bypass grafting or congestive heart-failure (CHF) at NYHA 3-4 level ;and patients with history of uncontrollable hypertension, arrhythmias considered clinically significant by the investigator, or electrocardiogram (ECG) abnormalities. 15. HIV infection, or active HBV infection (HBsAg and/or HBcAb positive, with peripheral blood HBV DNA ≥1 x 103 IU/ mL), or active HCV infection (HCV antibody positive, HCV RNA≥500 IU/ mL). 16. Alcoholics (drinking more than 14 standard units per week. 1 standard unit contains 14g alcohol,such as 360mL beer or 45mL spirits with 40% alcohol or 150mL wine)within 2 weeks before screening, or patients with drug abuse. 17. Patients who participated in other study within the last 1 month. 18. Pregnant or nursing women. 19. Patients who are thought to be unsuitable for participating in the trial by the researchers because of other factors.
Conditions Breast Cancer
Phase NA
Enrollment 79
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a phase I/II, single-arm and open-label single-centre clinical trial with the aim to test the feasibility, safety and the efficacy, in terms of complete pathological response, of preoperative ablative radiotherapy in single fraction for selected breast cancer patients.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: Phase I — To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
  • Radiation: Phase II — The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.

Primary Outcomes

  • Phase I: Identify the maximum tolerated dose (MTD) (time frame:2 weeks)
  • Phase II: Evaluate efficacy measured in terms of pCR rate (time frame:8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-07-31
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 79 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: European Institute of Oncology
Principal Investigators:
  • Maria Cristina Leonardi (PRINCIPAL_INVESTIGATOR) - European Institute of Oncology
Contact Information
Study Contact:
Maria Cristina Leonardi, MD
+39 02 57489037
cristina.leonardi@ieo.it
Anna Morra, MD
+39 02 57489037
anna.morra@ieo.it
Maria Cristina Leonardi, MD
IEO, European Institute of Oncology IRCCS
Interventions
  • Radiation: Phase I — To establish the recommended dose defined as the maximum tolerated dose (MTD)The dose-limiting toxicity (DLT) is defined as any G3-G4 event according to NCI CTCAE Version 4.03 scale. Dose escalation is designed as a 3+3 rule-based study. Dose escalation will be initiated from a baseline dose of 18 Gy and increased to reach 21 Gy and 24 Gy. The population size includes 18 patients.
  • Radiation: Phase II — The recommended dose from the phase I study is delivered, using Cyberknife in order to evaluate the efficacy measured in terms of pCR rate. The population size includes 61 patients.
Study Locations (1 sites)
IEO, European Institute of Oncology IRCCS, Milan, 20141 Italy
Eligibility Criteria
Inclusion Criteria: * Histologically proven unifocal adenocarcinoma * T1-T2 * Tumor size up to 2.5 cm * cN0 * Age ≥ 18 years old * Good general condition (ECOG 0-2) * Planned BCS * Written informed consent Exclusion Criteria: * Tumor close to skin or chest wall * Pure non-invasive tumor * Prior RT to the chest * Neoadjuvant chemotherapy * Collagenopathies * Coagulation or autoimmunitary disorders * Previous malignancies
Conditions Kidney Transplant; Complications, Diabet...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The investigators want to study the impact CGM (continuous glucose monitoring) has on patients glycemic control as determined by time in range (TIR 70-180 mg/dL) in the Diabetic Kidney Transplant population.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Dexcom G6 — access to continuous glucose monitoring in the Dexcom G6 arm 24/7
  • Device: Dexcom G6 blinded sensor — retrospective access to continuous glucose profile after 10 days of wear

Primary Outcomes

  • Time in Range (70-180 mg/dl) (70 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-06-29
Completion: 2026-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of California, Davis
Collaborators: DexCom, Inc.
Principal Investigators:
  • Ling Chen, MD (STUDY_DIRECTOR) - UCDavis Transplant Nephrology
Contact Information
Study Contact:
Dahlia Zuidema, PharmD
916-734-4009
dmzuidema@ucdavis.edu
Clinical Research Coordinators
916-734-4009
HS-TransplantCenterResearch@ucdavis.edu
Dahlia Zuidema, PharmD
916-734-4009
dmzuidema@ucdavis.edu
UC Davis Health
Interventions
  • Device: Dexcom G6 — access to continuous glucose monitoring in the Dexcom G6 arm 24/7
  • Device: Dexcom G6 blinded sensor — retrospective access to continuous glucose profile after 10 days of wear
Study Locations (1 sites)
UC Davis Health, Sacramento, California 95817 United States
Eligibility Criteria
Inclusion Criteria: 1. Age 18 or above 2. Received a kidney transplant within the past year with functioning kidney (eGFR \> 30 mL/min 3. Person with Type 2 Diabetes and on insulin 4. Access to home wi-fi connection Exclusion Criteria: 1. Person with Type 1 Diabetes 2. Patients taking hydroxyurea 3. Patient unable to wear the Dexcom G6 device at all times for any reason 4. Must be able to test blood glucose with meter 4x a day when on blinded CGM. 5. Presence of clinically significant visual or cognitive impairment 6. Illiterate 7. Prisoners 8. Women who are pregnant, who plan to become pregnant during the course of the study, or who are breastfeeding 9. Presence of clinically unstable cardiovascular disease 10. Active malignancy treatment
Conditions Hypertension
Phase NA
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

According to the latest survey data of China hypertension annual meeting, there are about 300 million patients with hypertension in China, with 10 million new cases of hypertension each year, and there is an obvious trend of younger people. In particular, young and middle-aged people are in a state of mild hypertension for a long time, which causes great pressure on health and medical treatment. At present, the main clinical measures for mild hypertension are to change their eating habits, quit smoking and alcohol, exercise and other lifestyle changes, as well as drug control. For most patients with mild hypertension, drug control is not the best choice. It has been reported that remote ischemic preconditioning (RIPC) may play an effective role in reducing blood pressure .The purpose of this study was to investigate the extent of long-term application of RIPC to reduce blood pressure in patients with mild hypertension.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Factorial Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Device: CRIC — Remote Ischemic Conditioning (CRIC): Twice daily for 12 weeks using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg).
  • Behavioral: MFT — Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation.
  • Other: sham CRIC — Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation.
  • Other: sham MFT — Sham MFT: Twice daily equivalent-duration audio of looped neutral nature sounds (ocean waves, flowing water, birdsong) without mindfulness instructions.

Primary Outcomes

  • Mean systolic blood pressure (3 months)
  • Mean diastolic blood pressure (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-07-03
Completion: 2030-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Henan Institute of Cardiovascular Epidemiology
Principal Investigators:
  • Muwei Li, MD (STUDY_CHAIR) - Chinese Academy of Medical Sciences, Fuwai Hospital
Contact Information
Study Contact:
En Li
13525070525
1799077212@qq.com
Muwei Li, MD
+8613838083966
lmw0207@163.com
Fuwai central China Cardiovascular hospital
Interventions
  • Device: CRIC — Remote Ischemic Conditioning (CRIC): Twice daily for 12 weeks using an automated cuff device. Each 30-minute session consisted of 3 cycles of 6 min inflation (pressure individualized: resting SBP-based increments of +40/+30/+20 mmHg depending on baseline SBP level) followed by 4 min deflation (0 mmHg).
  • Behavioral: MFT — Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation.
  • Other: sham CRIC — Sham CRIC: Identical schedule and device; each cycle used fixed 5 min inflation at 60 mmHg (non-ischemic) followed by 5 min deflation.
  • Other: sham MFT — Sham MFT: Twice daily equivalent-duration audio of looped neutral nature sounds (ocean waves, flowing water, birdsong) without mindfulness instructions.
Study Locations (1 sites)
Fuwai central China Cardiovascular hospital, Zhengzhou, Henan 450008 China
Eligibility Criteria
Inclusion Criteria: * Diagnosed patients with mild hypertension (SBP: 140\~159mmHg; DBP: 90\~99mmHg) Exclusion Criteria: * Cannot tolerate RIPC * Non-essential hypertension * patients who have uncontrolled severe arrhythmia, diabetes, electrolyte disturbance * patients who have severe organic diseases such acute myocardial infarction, cardiac insufficiency, abnormal renal function, etc.
Conditions Asthma
Phase PHASE4
Enrollment 234
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The optimal duration of the treatment by OMA remains unclear when asthma is well controlled. Data suggest that a large part of patients with well controlled asthma can discontinue OMA therapy without any asthma control deterioration or with an acceptable decrease in asthma control, therefore French experts propose that omalizumab can be given for "3 to 5 yrs if asthma remains well controlled". The costs related to OMA are high and frequent injections represent severe constraints for patients. For all these reasons, evaluating whether shortening duration of OMA therapy is feasible while maintaining acceptable asthma control is a critical point. Therefore, the aim of this study is to evaluate asthma control after OMA discontinuation after at least 33 months of treatment when asthma is well controlled.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Other: Attempt to withdrawal OMA treatment — Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line
  • Drug: Continuation of OMA treatment — Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels. In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care.

Primary Outcomes

  • Number of exacerbations (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2021-05-20
Completion: 2027-05-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 234 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Principal Investigators:
  • Camille TAILLE, Professor (PRINCIPAL_INVESTIGATOR) - Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Camille TAILLE, Professor
01 40 25 68 63
camille.taille@aphp.fr
Yannick VACHER, Chef de projet DRCI
01.44.84.17.30
yannick.vacher@aphp.fr
Hôpital Bichat-Claude Bernard
Eve KLISING, Chef de projet CEPHEPI
01 42 16 75 83
eve.klising@aphp.fr
Hôpital Bichat-Claude Bernard
Interventions
  • Other: Attempt to withdrawal OMA treatment — Patients will be told to stop abruptly (no progressive decrease of the dose) their Omalizumab treatment and they will not be prescribed new OMA. In case of loss of control, pulmonologist can adapt asthma treatment, as in usual care. In that case, OMA can be prescribed for a second line
  • Drug: Continuation of OMA treatment — Patients will be prescribed the same dosage of Omalizumab than they received before randomization, according to their weight and total circulating IgE levels. In case of safety concerns or loss of control, pulmonologist can modify the patient treatment regimen of OMA or other co-medications, as in usual care.
Study Locations (1 sites)
Hôpital Bichat-Claude Bernard, Paris, Île-de-France Region 75018 France
Eligibility Criteria
Inclusion Criteria: * Adult patient \>18 years old * Treated with OMA, prescribed by a pulmonologist , for at least 33 months for severe allergic asthma * Well controlled with the treatment (ACT score ⩾ 18) and having experienced no more than one exacerbation in the year preceding inclusion. An exacerbation is defined as an oral or injectable steroid course for at least 2 days and/or a minimum doubling of the usual steroid dose for at least 2 days for steroid dependent patients Exclusion Criteria: * Patient refusing to stop OMA treatment, whatever the reason * Patient with other reason other than good asthma control to stop OMA, such as a side effect, planned or ongoing pregnancy, or planned switch to another step 5 asthma treatment (mepolizumab, benralizumab, dupilumab, reslizumab, daily oral steroids, bronchial thermoplasty, …) * Patient not covered by Health Insurance * Patient under curatorship, guardianship or safeguarding of justice * Patient whose adherence to asthma treatments is considered poor or questionable by the investigator * Patient participating in another intervention research * Pregnant or lactating patient * Patient refusing to sign consent
Conditions Educational Materials for Genetic Testin...
Phase NA
Enrollment 445
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Genetic testing is a type of test that detects changes to the genes-the DNA instructions that are passed on from the mother and father. The results of a genetic test can confirm whether the participant has a genetic disorder, which is a disease caused in whole or in part by changes to the genes. Genetic testing can also help determine a person's chance of getting or passing on a genetic disorder. Genetic tests use a sample of blood, hair, skin, or other tissue, and they can look at one gene or multiple genes at the same time. Genetic testing may change the options for treating people with certain types of cancer. For example, some medications are more helpful for the treatment of cancer in people with certain gene changes (mutations). The researchers are doing this study to develop new educational materials about genetic testing for people who speak different languages and have diverse cultural and educational backgrounds. During the study, the staff will interview participants with diverse cultural and educational backgrounds and ask them to review a sample of the educational materials that have been developed so far. Participants will give their opinions on these materials, and the researchers will use participants' feedback to improve the materials.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Cognitive interview — Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
  • Behavioral: LCAM intervention — Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials.
  • Behavioral: Standard of care — Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics

Primary Outcomes

  • Number of patients who complete the cognitive interview (Phase I) (1 year)
  • Genetic test decision (Phase II) satisfaction (6 months)
  • Genetic counseling satisfaction (Phase II) (6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-11-16
Completion: 2027-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 445 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Principal Investigators:
  • Jada Hamilton, PhD, MPH (PRINCIPAL_INVESTIGATOR) - Memorial Sloan Kettering Cancer Center
Contact Information
Study Contact:
Jada Hamilton, PhD, MPH
646-888-0049
hamiltoj@mskcc.org
Jennifer Hay, PhD
646-888-0039
Jason Gonsky, MD
718-245-2847
Kings County Hopsital Center
Interventions
  • Other: Cognitive interview — Researchers will use formative methods to adapt our previously-developed mainstreaming pre-genetic test educational materials plus standard post-test clinical communication materials used by the MSK CGS for use with the diverse patients. Specifically, it will adapt these materials to be responsive to patients' linguistic and literacy needs, and sensitive to their cultural diversity.
  • Behavioral: LCAM intervention — Participants will receive adapted pretest educational materials from study staff and/or clinical staff and have testing ordered by their oncologist, followed by post-test genetic counseling via telegenetics with a health and genetic "literacy screener" and adapted clinical communication materials.
  • Behavioral: Standard of care — Participants will receive in-depth pre-test and post-test genetic counseling provided via telegenetics
Study Locations (4 sites)
Kings County Hopsital Center, Brooklyn, New York 11203 United States
Queens Cancer Center of Queens Hospital, Jamaica, New York 11432 United States
Memorial Sloan Kettering at Ralph Lauren Center (Limited Protocol Activities), New York, New York 10035 United States
Jamaica Hospital Medical Center (Data Collection Only), Richmond Hill, New York 11418 United States
Eligibility Criteria
Inclusion Criteria: Phase 1 * Age ≥ 18 years as per self-report * Current or previous diagnosis of breast, ovarian, pancreatic, or prostate cancer as per self-report * Self-identification as Black, Latino, and/or neither Black nor Latino (i.e.,non-Latino, Non black) * Fluency in English, Haitian Creole, or Spanish as per self-report (for Spanish, we will attempt to recruit a cohort representing a variety of regions where Spanish is spoken, as informed by current data from participating sites, to achieve neutrality in the language) Fluency is defined as an answer of "well" or "very well" on the screening questions for spoken and reading ability. Phase 2: * Age ≥ 18 years as per the medical record and/or clinician referral * Current or previous diagnosis of breast, colorectal, ovarian, pancreatic, or prostate cancer meeting at least one of the applicable criteria for the cancer type as per the medical record and/or clinician referral: * Breast cancer criteria: * any diagnosis age 65 or younger; * diagnosis of triple negative breast cancer at any age; * multiple primary breast cancers at any age; * under consideration for PARP therapy; * any family history (1st, 2nd, or 3rd degree relatives) of ovarian or pancreas cancer, or 1 relative with breast cancer who meets the above criteria, or 2 relatives with breast cancer at any age; or clinician discretion) * Colorectal cancer criteria: * any diagnosis age 50 and below; * mismatch repair deficient colorectal cancer; * colorectal cancer at any age with an additional Lynch syndromerelated primary cancer at any age; * colorectal cancer at any age with a 1st or 2nd degree relative with colorectal cancer at/before age 50; * colorectal cancer at any age with 2 or more 1st or 2nd degree relatives with a Lynch syndrome-related cancer at any age * Ovarian cancer criteria: ° invasive ovarian cancer * Pancreatic cancer criteria: ° pancreatic adenocarcinoma * Prostate cancer criteria: * castrate-resistant, metastatic prostate cancer; * high-risk prostate cancer (pending pathology definition) * Fluency in English, Haitian Creole, or Spanish as per self-report. Fluency is defined as an answer of "well" or "very well" on the screening questions for spoken ability * No prior cancer genetic counseling or germline testing for cancer risk as per self-report clinician's note, and/or no clinical documentation Exclusion Criteria: Phase 1: * Individuals of impaired decision-making capacity as per a clinician's or consenting professional's judgment. * Subjects who indicate level of fluency as "not at all" or "not well". Phase 2: * Individuals of impaired decision-making capacity as per a clinician's or consenting professional's judgment. * Subjects who indicate level of fluency as "not at all" or "not well".
Conditions Breast Cancer
Phase PHASE2, PHASE3
Enrollment 260
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Circulating tumor DNA (ctDNA) has been demonstrated to be an effective prognostic marker in breast cancer. Various studies have shown that early TNBC breast cancer patients with positive ctDNA have high risk of cancer recurrence and worse prognosis. This study aimed to identify TNBC patients with positive ctDNA and initiate boost therapy in these high risk patients.

Design

Study type: Interventional Phases: Phase2, Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: capecitabine — capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
  • Drug: capecitabine + camrelizumab + apatinib — Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study

Primary Outcomes

  • Invasive Disease Free Survival(IDFS) (60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2, PHASE3
Status: Recruiting
Start Date: 2021-04-01
Completion: 2033-09-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Principal Investigators:
  • Qiang Liu, PhD (PRINCIPAL_INVESTIGATOR) - Sunyat-sen Memorial Hospital
Contact Information
Study Contact:
Shunying Li, MD
86-020-34071156
lishunying@foxmail.com
Qiang Liu, PhD
86-020-34071157
victorlq@hotmail.com
shunying Li
+86-15915939702
lishunying@foxmail.com
Sunyat-sen Memorial Hospital
Interventions
  • Drug: capecitabine — capecitabine is proved to improve 5-year disease-free survival among women with early-stage triple-negative breast cancer who received standard adjuvant treatment(The SYSUCC-001 Randomized Clinical Trial)
  • Drug: capecitabine + camrelizumab + apatinib — Camrelizumab combined with apatinib is a safe and effective combination proved in patients with advanced TNBC in our early study
Study Locations (1 sites)
Sunyat-sen Memorial Hospital, Guandong, Guangdong China
Eligibility Criteria
Inclusion Criteria: * Patient is ≥ 18 years-old at the time of consent to participate this trial * Stage II - III primary triple negative breast cancer patients(TNBC), TNBC is defined as ER \<=1%, PR \<=1%;HER2 receptor IHC=1, or IHC=2 and FISH negative. * positive ctDNA after curative surgery and/or adjuvant chemotherapy * ECOG 0-2 * If indicated, patient agree to receive adjuvant radiotherapy according to the institutional guidelines * Patient receives adjuvant chemotherapy according to the NCCN guidelines * Patient has available tumor tissue from the surgical specimen for next generation sequencing(NCS) * Patient agrees to give blood samples for ctDNA tests every 3 months in 5 years Exclusion Criteria: * Patient has previously received any PD1/PDL1 blockage treatment * Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or breast-feed during the trial * Patient with distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) * Patient participates another interventional clinical trial * Patient has a concurrent invasive malignancy or a prior invasive malignancy whose treatment was completed within 3 years before randomization * Patient with autoimmune disease preventing the use of camrelizumab * Patient has any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical trial or compromise compliance with the protocol
Conditions Breast Cancer
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients with localized hormone-dependent breast cancer. 200 patients will be included in the study. Each patient will be followed for one day.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Other Masking/blinding: None

Interventions / Regimen

  • Other: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen. — Each included patient will be referred to the health care staff for a blood sample: * for the determination of the residual plasma concentration of tamoxifen and its active metabolites, * for the constitution of a biobank. Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...).

Primary Outcomes

  • Rate of patients who adhere to tamoxifen treatment. (18 months after the start of the research)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2021-02-12
Completion: 2028-02
Eligibility
Age: 18 Months and older
Sex: FEMALE
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institut Claudius Regaud
Contact Information
Study Contact:
Florence DALENC
05 31 15 51 04
dalenc.florence@iuct-oncopole.fr
Florence DALENC
05 31 15 51 04
dalenc.florence@iuct-oncopole.fr
Institut Universitaire du Cancer de Toulouse - Oncopole
Interventions
  • Other: Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen. — Each included patient will be referred to the health care staff for a blood sample: * for the determination of the residual plasma concentration of tamoxifen and its active metabolites, * for the constitution of a biobank. Patients will then complete a questionnaire to collect information on tamoxifen intake and adherence (via the GIRERD questionnaire), as well as possible Alternative and Complementary Therapeutics (ACT) intake (reason for use, type of ACT, ...).
Study Locations (1 sites)
Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, 31059 France
Eligibility Criteria
Inclusion Criteria: 1. Age ≥ 18 years at entry into the study. 2. Patient treated for hormone-dependent localized breast cancer requiring adjuvant Hormonal Therapy (HT) with tamoxifen. 3. Patients treated with tamoxifen for a maximum of 1 to 3 years. 4. Patient affiliated with a Social Security system in France. 5. Patients who signed informed consent prior to inclusion in the study and prior to any specific study procedures. Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Any psychological, family, geographical or sociological condition that does not allow the medical follow-up and/or the procedures foreseen in the study protocol to be respected. 3. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).